Navigation Links
Perrigo Confirms FDA Approval For Testosterone Gel 1%
Date:2/5/2013

ALLEGAN, Mich., Feb. 5, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel® 1%.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."          

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
2. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
3. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
4. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
7. Perrigo Company To Present At The Credit Suisse Healthcare Conference
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Bio-Techne Corporation has partnered with Brazil ... diagnostic tool for the veterinary market. The PARATEST ... the only non-toxic, biodegradable fixative available to the ... Bio-Techne,s Diagnostic Division in Devens, MA ... manufacturing, and packaging capabilities to bring this unique ...
(Date:3/1/2017)... Research and Markets has announced the addition of ... & Infectious Diseases" report to their offering. ... Did you know? - ... Genomic Health, Inc.. - Beijing Wantai Biological Pharmacy,s Beijing ... infectious diseases diagnostics in China . - MDxHealth ...
(Date:3/1/2017)... HOUSTON , March 1, 2017  The Welch ... funding for basic research, today announced that Drs. ... are the 2017 recipients of the Norman ... being recognized as ,rising stars, having contributed significant scientific ... the first time in the 15 years of the ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... of eating disorders, is pleased to announce the opening of residential services, in ... this week, Aloria Health will accept adult clients for residential treatment. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Hennessey Performance (HPE) today announced its VelociRaptor 600 ... Ford EcoBoost 3.5L twin turbo V6 engine from 450 bhp and 510 lb-ft of torque ... a 0-60 mph time of just 4.2 seconds while running down the ¼ mile in ...
(Date:3/1/2017)... ... March 01, 2017 , ... Both incentives ... Supplemental Nutrition Assistance Program (SNAP) can reduce food insecurity. Findings are presented in ... the American Journal of Preventive Medicine . , Researchers examined data from two ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 01, 2017 , ... Award-winning medical group Allied Anesthesia today announced that, as ... nations, averaging more than one trip per year since 1998. Char was named the ... features the details of his charitable work. Char has been an Allied Anesthesiologist since ...
Breaking Medicine News(10 mins):